Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,266Revenue $M173Net Margin (%)58.3Altman Z-Score32.7
Enterprise Value $M1,066EPS $3.3Operating Margin %66.1Piotroski F-Score4
P/E(ttm)15.1Beneish M-Score--Pre-tax Margin (%)66.1Higher ROA y-yY
Price/Book5.410-y EBITDA Growth Rate %--Quick Ratio14.3Cash flow > EarningsN
Price/Sales6.75-y EBITDA Growth Rate %--Current Ratio14.3Lower Leverage y-yN
Price/Free Cash Flow17.7y-y EBITDA Growth Rate %--ROA % (ttm)81.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)93.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M28.6ROIC % (ttm)1,345Gross Margin Increase y-yN

Gurus Latest Trades with NLNK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NLNKJoel Greenblatt 2015-03-31 Buy 0.35%$31.95 - $56.4
($43.06)
$ 44.273%New holding838,221
NLNKFirst Eagle Investment 2015-03-31 Add$31.95 - $56.4
($43.06)
$ 44.273%Add 1.73%1,430,700
NLNKFirst Eagle Investment 2014-03-31 Add0.02%$21.38 - $50.4
($33.68)
$ 44.2731%Add 28.35%1,161,805
NLNKFirst Eagle Investment 2013-09-30 Add0.01%$15.78 - $20.08
($17.83)
$ 44.27148%Add 21.32%778,354
NLNKFirst Eagle Investment 2013-06-30 Add0.02%$11.27 - $22.56
($15.73)
$ 44.27181%Add 95.04%641,554
NLNKFirst Eagle Investment 2013-03-31 Buy 0.01%$11.4 - $12.7
($12.08)
$ 44.27266%New holding328,939
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NLNK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NLNK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ramsey William J.Quality Assurance Officer 2015-02-17Sell2,500$4010.68view
Wiley BrianVP of Business Development 2015-02-17Sell10,000$40.0710.48view
Link Charles J. Jr.Chairman of the Board and CEO 2015-02-05Sell20,000$32.4136.59view
Ramsey William J.Quality Assurance Officer 2015-01-23Sell2,500$4010.68view
Link Charles J. Jr.Chairman of the Board and CEO 2015-01-07Sell20,000$37.9916.53view
Wiley BrianVP of Business Development 2015-01-02Sell20,000$40.339.77view
Link Charles J. Jr.Chairman of the Board and CEO 2014-12-04Sell20,000$37.8416.99view
HENNEMAN JOHN B IIIEVP, CFO 2014-11-25Buy5,000$34.3528.88view
Link Charles J. Jr.Chairman of the Board and CEO 2014-11-10Sell20,000$32.9434.4view
LINK GORDON H JRCFO 2014-10-24Sell2,500$40.399.61view

Quarterly/Annual Reports about NLNK:

News about NLNK:

Articles On GuruFocus.com
These Companies Show High Profit and Low Debt Jun 17 2015 
When A Stock Doubles, Don’t Trim It Automatically May 27 2015 
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers May 29 2015
NewLink Genetics to Present at the Jefferies Global Healthcare Conference May 29 2015
NewLink Genetics to Present Poster on Indoximod, an IDO Pathway Inhibitor, at American Society of... May 26 2015
NewLink Genetics to Present Poster on Indoximod, an IDO Pathway Inhibitor, at American Society of... May 26 2015
NEWLINK GENETICS CORP Financials May 20 2015
The 5 Winners and Losers From ASCO Presentations May 14 2015
Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog May 13 2015
NewLink Genetics shares fall on study continuation May 12 2015
NewLink Genetics shares fall on study continuation May 12 2015
Stocks Stumble In Rising Trade; Pall Soars, NewLink Dives May 12 2015
As Ebola disappears, no useful data seen from vaccine trials -WHO May 12 2015
As Ebola disappears, no useful data seen from vaccine trials -WHO May 12 2015
NewLink's Pancreatic Cancer Vaccine on Long Road to Study Failure May 12 2015
Virtusa, Ocean Rig, magicJack Lead Monday's After-Hours Movers May 11 2015
Rackspace shares fall on revenue outlook May 11 2015
After-hours buzz: Rackspace, Gap, Depomed & more May 11 2015
Newlink shares drop as study data analysis plan goes unchanged May 11 2015
NewLink Genetics' IMPRESS Phase 3 Pancreatic Cancer Trial with Algenpantucel-L to Continue Following... May 11 2015
NEWLINK GENETICS CORP Files SEC form 10-Q, Quarterly Report May 11 2015
NewLink Genetics' IMPRESS Phase 3 Pancreatic Cancer Trial with Algenpantucel-L to Continue Following... May 11 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK